

Global Pharmacovigilance and Drug Safety Software Market Report and Forecast 2023-2031

Market Report | 2023-04-27 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Pharmacovigilance and Drug Safety Software Market Report and Forecast 2023-2031

Global Pharmacovigilance and Drug Safety Software Market Outlook

The value of the global pharmacovigilance and drug safety software market was USD 7.80 billion in 2022, driven by the increasing incidence of adverse drug reactions across the globe. The market value is anticipated to grow at a CAGR of 8.98% during the forecast period of 2023-2031 to reach a value of USD 16.90 billion by 2031.

Pharmacovigilance and Drug Safety Software: Introduction

Pharmacovigilance and drug safety software is a computer-based system used by pharmaceutical companies to monitor and analyse the safety of drugs in the market. The software collects, analyses, and evaluates data related to the adverse effects of drugs, identifies potential risks, and suggests measures to manage and mitigate those risks. It helps in ensuring the safety and efficacy of drugs, improving patient outcomes, and complying with regulatory requirements. The software can also generate reports and alerts based on the analysed data, enabling healthcare professionals and regulators to take informed decisions about the use of drugs.

Pharmacovigilance and Drug Safety Software: Application and Uses

Pharmacovigilance and drug safety software are used in the healthcare industry to monitor and track the safety of drugs and medications. The software is designed to help healthcare professionals and regulatory agencies identify and evaluate adverse events, including side effects, drug interactions, and other safety issues related to medications. The application and uses of pharmacovigilance and drug safety software include:

- Adverse Event Reporting: Pharmacovigilance software is used to track adverse events and report them to regulatory agencies as required.
- Signal Detection: The software can be used to identify new signals or trends in safety data, such as increased rates of adverse events for a particular drug.
- Risk Management: Pharmacovigilance software is used to manage and mitigate risks associated with drugs and medications.
- Clinical Trial Safety Monitoring: The software can be used to monitor safety data during clinical trials and help ensure that trials

are conducted safely and ethically.

- Post-Marketing Surveillance: Pharmacovigilance software is used to monitor safety data after a drug is approved and on the market.
- Regulatory Compliance: The software is designed to help healthcare organizations comply with regulatory requirements related to drug safety and pharmacovigilance.

Overall, pharmacovigilance and drug safety software are critical tools for ensuring the safety and efficacy of drugs and medications, and are used throughout the healthcare industry to improve patient safety and outcomes.

Global Pharmacovigilance and Drug Safety Software Market Segmentations

Market Breakup by Functionality

- -□Adverse Event Reporting Software
- -∏Drug Safety Audits Software
- -∏Issue Tracking Software
- -□Fully Integrated Software

Market Breakup by Mode of Delivery

- On-Premises Delivery
- On-Demand/Cloud Based (SaaS) Delivery

Market Breakup by End User

- Pharma and Biotech Companies
- -□Contract Research Organizations (CROs)
- Business Process Outsourcing (BPO) Firms
- -∏Others

Market Breakup by Region

North America

- -□United States of America
- -[]Canada

Europe

- United Kingdom
- -∏Germany
- -[]France
- -[]Italy
- -□Others

Asia Pacific

- -[China
- -∐apan
- -[]India
- ASEAN
- -∏Australia
- -[Others

Latin America

-[Brazil

Scotts International, EU Vat number: PL 6772247784

- -[]Argentina
- -□Mexico
- Others

Middle East and Africa

- -∏Saudi Arabia
- -□United Arab Emirates
- -∏Nigeria
- -□South Africa
- -∏Others

Global Pharmacovigilance and Drug Safety Software Market Scenario

The market is expected to grow significantly during the forecast period owing to the increasing incidence of adverse drug reactions and the growing emphasis on patient safety and risk management are some of the key factors driving the growth of this market.

The market is also being driven by the increasing demand for pharmacovigilance and drug safety software solutions among pharmaceutical and biotechnology companies, contract research organizations, and regulatory authorities. In addition, the increasing use of artificial intelligence and machine learning in pharmacovigilance and drug safety software is expected to fuel the growth of this market.

Based on the mode of delivery, the cloud-based segment is expected to witness significant growth during the forecast period due to its advantages such as easy access to data, reduced cost of ownership, and improved scalability. On the basis of end-users, the pharmaceutical and biotechnology company segment is expected to hold the largest share of the market owing to the increasing need for pharmacovigilance and drug safety software solutions in these companies.

Geographically, North America is expected to dominate the global pharmacovigilance and drug safety software market owing to the presence of a large number of pharmaceutical and biotechnology companies and stringent regulatory requirements. However, the Asia Pacific region is expected to witness significant growth during the forecast period due to the increasing number of clinical trials being conducted in this region and the increasing focus on patient safety and risk management.

Overall, the pharmacovigilance and drug safety software market is expected to experience steady growth during the forecast period due to the increasing demand for pharmacovigilance and drug safety solutions and the growing emphasis on patient safety and risk management.

Key Players in the Global Pharmacovigilance and Drug Safety Software Market

The report gives an in-depth analysis of the key players involved in the global pharmacovigilance and drug safety software market. The companies included in the market are as follows:

- -∏IQVIA
- Accenture
- -□Cognizant
- Laboratory Corporation of America Holdings
- -∏IBM
- -∏ARIS Global
- -∏ICON Plc.
- -[Capgemini
- -[]Oracle
- -□Parexel International Corporation
- -∏Ab Cube
- -∏Extedo GmbH
- Ennov Solutions Inc.

Scotts International, EU Vat number: PL 6772247784

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Pharmacovigilance and Drug Safety Software Market Overview
 - 3.1 Global Pharmacovigilance and Drug Safety Software Market Historical Value (2016-2022)
 - 3.2 Global Pharmacovigilance and Drug Safety Software Market Forecast Value (2023-2031)
- 4 Global Pharmacovigilance and Drug Safety Software Market Landscape
 - 4.1 Global Pharmacovigilance and Drug Safety Software Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Pharmacovigilance and Drug Safety Software Product Landscape
 - 4.2.1 Analysis by Functionality
 - 4.2.2 Analysis by Mode of Mode of Delivery
 - 4.2.3 Analysis by End User
- 5 Global Pharmacovigilance and Drug Safety Software Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Pharmacovigilance and Drug Safety Software Market Segmentation
 - 6.1 Global Pharmacovigilance and Drug Safety Software Market by Functionality
 - 6.1.1 Market Overview
 - 6.1.2 Adverse Event Reporting Software
 - 6.1.3 Drug Safety Audits Software
 - 6.1.4 Issue Tracking Software
 - 6.1.5 Fully Integrated Software
 - 6.2 Global Pharmacovigilance and Drug Safety Software Market by Mode of Delivery
 - 6.2.1 Market Overview
 - 6.2.2 On-Premises Delivery
 - 6.2.3 On-Demand/Cloud Based (SaaS) Delivery
 - 6.3 Global Pharmacovigilance and Drug Safety Software Market by End User
 - 6.3.1 Market Overview
 - 6.3.2 Pharma and Biotech Companies
 - 6.3.3 Contract Research Organizations (CROs)
 - 6.3.4 Business Process Outsourcing (BPO) Firms
 - 635 Others
 - 6.4 Global Pharmacovigilance and Drug Safety Software Market by Region
 - 6.4.1 Market Overview
 - 6.4.2 North America

- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Pharmacovigilance and Drug Safety Software Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Pharmacovigilance and Drug Safety Software Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Pharmacovigilance and Drug Safety Software Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India
 - 9.5 ASFAN
 - 9.6 Australia
 - 9.7 Others
- 10 Latin America Pharmacovigilance and Drug Safety Software Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Pharmacovigilance and Drug Safety Software Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded

Scotts International. EU Vat number: PL 6772247784

- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
 - 14.1 Analysis by Funding Instances
 - 14.2 Analysis by Type of Funding
 - 14.3 Analysis by Funding Amount
 - 14.4 Analysis by Leading Players
 - 14.5 Analysis by Leading Investors
 - 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
 - 15.1 Analysis by Partnership Instances
 - 15.2 Analysis by Type of Partnership
 - 15.3 Analysis by Leading Players
 - 15.4 Analysis by Geography
- 16 Regulatory Framework
 - 16.1 Regulatory Overview
 - 16.1.1 US FDA
 - 16.1.2 EU EMA
 - 16.1.3 INDIA CDSCO
 - 16.1.4 JAPAN PMDA
 - 16.1.5 Others
- 17 Supplier Landscape
 - 17.1 IQVIA
 - 17.1.1 Financial Analysis
 - 17.1.2 Product Portfolio
 - 17.1.3 Demographic Reach and Achievements
 - 17.1.4 Mergers and Acquisitions
 - 17.1.5 Certifications
 - 17.2 Accenture
 - 17.2.1 Financial Analysis
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisitions
 - 17.2.5 Certifications
 - 17.3 Cognizant
 - 17.3.1 Financial Analysis
 - 17.3.2 Product Portfolio
 - 17.3.3 Demographic Reach and Achievements
 - 17.3.4 Mergers and Acquisitions
 - 17.3.5 Certifications
 - 17.4 Laboratory Corporation of America Holdings
 - 17.4.1 Financial Analysis
 - 17.4.2 Product Portfolio
 - 17.4.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 IBM
 - 17.5.1 Financial Analysis
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements
 - 17.5.4 Mergers and Acquisitions
 - 17.5.5 Certifications
- 17.6 ARIS Global
 - 17.6.1 Financial Analysis
 - 17.6.2 Product Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Mergers and Acquisitions
 - 17.6.5 Certifications
- 17.7 ICON Plc.
 - 17.7.1 Financial Analysis
 - 17.7.2 Product Portfolio
 - 17.7.3 Demographic Reach and Achievements
 - 17.7.4 Mergers and Acquisitions
 - 17.7.5 Certifications
- 17.8 Capgemini
 - 17.8.1 Financial Analysis
 - 17.8.2 Product Portfolio
 - 17.8.3 Demographic Reach and Achievements
 - 17.8.4 Mergers and Acquisitions
 - 17.8.5 Certifications
- 17.9 Oracle
 - 17.9.1 Financial Analysis
 - 17.9.2 Product Portfolio
 - 17.9.3 Demographic Reach and Achievements
 - 17.9.4 Mergers and Acquisitions
 - 17.9.5 Certifications
- 17.10 Parexel International Corporation
 - 17.10.1 Financial Analysis
 - 17.10.2 Product Portfolio
 - 17.10.3 Demographic Reach and Achievements
 - 17.10.4 Mergers and Acquisitions
 - 17.10.5 Certifications
- 17.11 Ab Cube
 - 17.11.1 Financial Analysis
 - 17.11.2 Product Portfolio
 - 17.11.3 Demographic Reach and Achievements
 - 17.11.4 Mergers and Acquisitions
 - 17.11.5 Certifications
- 17.12 Extedo GmbH
 - 17.12.1 Financial Analysis
 - 17.12.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Ennov Solutions Inc.
 - 17.13.1 Financial Analysis
 - 17.13.2 Product Portfolio
 - 17.13.3 Demographic Reach and Achievements
 - 17.13.4 Mergers and Acquisitions
 - 17.13.5 Certifications
- 18 Global Pharmacovigilance and Drug Safety Software Market Distribution Model (Additional Insight)
 - 18.1 Overview
 - 18.2 Potential Distributors
 - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
 - 20.1 Very Small Companies
 - 20.2 Small Companies
 - 20.3 Mid-Sized Companies
 - 20.4 Large Companies
 - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
 - 21.1 Government Funded
 - 21.2 Private Insurance
 - 21.3 Out-of-Pocket



Global Pharmacovigilance and Drug Safety Software Market Report and Forecast 2023-2031

Market Report | 2023-04-27 | 147 pages | EMR Inc.

To place an Order wi	th Scotts International:			
- Print this form				
☐ - Complete the re	elevant blank fields and sign			
Send as a scann	ned email to support@scotts-intern	ational.com		
ORDER FORM:				
Select license	License			Price
	Single User License			\$5999.00
	Five User License			\$7999.00
	Corporate License			\$9999.00
			VAT	
			Total	
			scotts-international.com or 0048 603 3	
** VAT will be added a	t 23% for Polish based companies, indi	viduals and EU based c	ompanies who are unable to provide a	valid EU Vat Numbers
Email*		Phone*		\neg
Elliali.		Phone:		
First Name*		Last Name*		
Job title*				
Company Name* [EU Vat / Tax ID /	NIP number*	
Address*		City*		
Zip Code*		Country*		
		Date	2025-05-07	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature

1	